Enwei Pharmaceutical Co., Ltd. (SHE:301331)

China flag China · Delayed Price · Currency is CNY
33.26
-0.73 (-2.15%)
Last updated: Sep 23, 2025, 10:15 AM CST
-2.15%
Market Cap3.19B
Revenue (ttm)873.20M
Net Income (ttm)57.91M
Shares Out101.08M
EPS (ttm)0.58
PE Ratio54.60
Forward PEn/a
Dividend0.18 (0.56%)
Ex-Dividend DateMay 28, 2025
Volume259,900
Average Volume1,108,414
Open33.31
Previous Close33.99
Day's Range33.26 - 34.10
52-Week Range21.12 - 39.66
Beta0.75
RSI37.04
Earnings DateOct 24, 2025

About Enwei Pharmaceutical

Enwei Pharmaceutical Co., Ltd. develops and sells Chinese medicines in China. It offers drugs in the areas of gynecology, pediatrics, respiratory system, and other pharmaceutical fields. The company was founded in 2005 and is based in Chengdu, China. [Read more]

Sector Healthcare
Founded 2005
Employees 1,548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301331
Full Company Profile

Financial Performance

In 2024, Enwei Pharmaceutical's revenue was 812.13 million, an increase of 3.43% compared to the previous year's 785.19 million. Earnings were 37.50 million, a decrease of -56.56%.

Financial Statements

News

There is no news available yet.